Celldex Therapeutics Inc
CLDX26.400USD
-0.430-1.60%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.75BMarket Cap
LossP/E TTM
More Details of Celldex Therapeutics Inc Company
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Celldex Therapeutics Inc Info
Ticker SymbolCLDX
Company nameCelldex Therapeutics Inc
IPO dateMay 15, 1986
CEOMarucci (Anthony S)
Number of employees186
Security typeOrdinary Share
Fiscal year-endMay 15
Address53 Frontage Road
CityHAMPTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08827
Phone19084547120
Websitehttps://celldex.com/
Ticker SymbolCLDX
IPO dateMay 15, 1986
CEOMarucci (Anthony S)
Company Executives of Celldex Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
29.20K
-12.49%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Mr. Herbert J. (Herb) Conrad
Mr. Herbert J. (Herb) Conrad
Independent Director
Independent Director
2.56K
--
Mr. James J. (Jim) Marino
Mr. James J. (Jim) Marino
Independent Director
Independent Director
2.20K
--
Mr. Keith L. Brownlie, CPA
Mr. Keith L. Brownlie, CPA
Independent Director
Independent Director
666.00
--
Ms. Teri L. Lawver
Ms. Teri L. Lawver
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
29.20K
-12.49%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
11.13%
Kynam Capital Management LP
9.18%
BlackRock Institutional Trust Company, N.A.
6.85%
The Vanguard Group, Inc.
5.93%
Point72 Asset Management, L.P.
5.86%
Other
61.05%
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
11.13%
Kynam Capital Management LP
9.18%
BlackRock Institutional Trust Company, N.A.
6.85%
The Vanguard Group, Inc.
5.93%
Point72 Asset Management, L.P.
5.86%
Other
61.05%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.48%
Hedge Fund
32.83%
Investment Advisor/Hedge Fund
31.61%
Venture Capital
2.69%
Research Firm
2.39%
Bank and Trust
0.38%
Pension Fund
0.32%
Individual Investor
0.30%
Insurance Company
0.04%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
423
73.56M
131.89%
+1.59M
2025Q3
430
71.99M
131.15%
-2.21M
2025Q2
424
73.79M
132.42%
-1.31M
2025Q1
421
75.04M
133.66%
-13.71M
2024Q4
421
74.73M
125.30%
+1.68M
2024Q3
414
73.10M
121.03%
+1.84M
2024Q2
417
71.21M
123.61%
+212.73K
2024Q1
405
71.18M
106.49%
+1.00M
2023Q4
395
62.54M
112.65%
+8.43M
2023Q3
391
51.91M
128.09%
+289.51K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wellington Management Company, LLP
5.23M
7.88%
-3.12M
-37.37%
Jun 30, 2025
Kynam Capital Management LP
6.10M
9.19%
-399.27K
-6.14%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.59M
6.91%
-38.52K
-0.83%
Jun 30, 2025
The Vanguard Group, Inc.
3.94M
5.94%
+56.45K
+1.45%
Jun 30, 2025
Point72 Asset Management, L.P.
2.80M
4.22%
+180.55K
+6.89%
Jun 30, 2025
Bellevue Asset Management AG
3.31M
4.98%
+235.95K
+7.68%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.95M
5.95%
+62.97K
+1.62%
Jun 30, 2025
Commodore Capital LP
3.45M
5.2%
+100.00K
+2.99%
Jun 30, 2025
State Street Investment Management (US)
2.41M
3.62%
-400.86K
-14.28%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.75M
5.65%
+398.14K
+11.88%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
3.36%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
ALPS Medical Breakthroughs ETF
0.74%
State Street SPDR S&P Biotech ETF
0.64%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
Avantis US Small Cap Equity ETF
0.16%
First Trust Small Cap Growth AlphaDEX Fund
0.15%
Nuveen ESG Small-Cap ETF
0.14%
T Rowe Price Small-Mid Cap ETF
0.13%
Fidelity Fundamental Small-Mid Cap ETF
0.13%
View more
Simplify Propel Opportunities ETF
Proportion3.36%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.89%
ALPS Medical Breakthroughs ETF
Proportion0.74%
State Street SPDR S&P Biotech ETF
Proportion0.64%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.39%
Avantis US Small Cap Equity ETF
Proportion0.16%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.15%
Nuveen ESG Small-Cap ETF
Proportion0.14%
T Rowe Price Small-Mid Cap ETF
Proportion0.13%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Celldex Therapeutics Inc?
The top five shareholders of Celldex Therapeutics Inc are:
Wellington Management Company, LLP holds 5.23M shares, accounting for 7.88% of the total shares.
Kynam Capital Management LP holds 6.10M shares, accounting for 9.19% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.59M shares, accounting for 6.91% of the total shares.
The Vanguard Group, Inc. holds 3.94M shares, accounting for 5.94% of the total shares.
Point72 Asset Management, L.P. holds 2.80M shares, accounting for 4.22% of the total shares.
Wellington Management Company, LLP holds 5.23M shares, accounting for 7.88% of the total shares.
Kynam Capital Management LP holds 6.10M shares, accounting for 9.19% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.59M shares, accounting for 6.91% of the total shares.
The Vanguard Group, Inc. holds 3.94M shares, accounting for 5.94% of the total shares.
Point72 Asset Management, L.P. holds 2.80M shares, accounting for 4.22% of the total shares.
What are the top three shareholder types of Celldex Therapeutics Inc?
The top three shareholder types of Celldex Therapeutics Inc are:
Wellington Management Company, LLP
Kynam Capital Management LP
BlackRock Institutional Trust Company, N.A.
Wellington Management Company, LLP
Kynam Capital Management LP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Celldex Therapeutics Inc (CLDX)?
As of 2025Q4, 423 institutions hold shares of Celldex Therapeutics Inc, with a combined market value of approximately 73.56M, accounting for 131.89% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.74%.
What is the biggest source of revenue for Celldex Therapeutics Inc?
In --, the -- business generated the highest revenue for Celldex Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
